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The aims of this study were 1) to determine whether the accumulation of coronary plaque burden 
assessed with coronary computed tomography angiography (CCTA) can predict future events, and 
2) to estimate the onset and progression of coronary atherosclerosis in patients with 
familial hypercholesterolemia (FH). Consecutive 101 Japanese heterozygous FH patients 
(male=52, mean age=56±16 years, mean LDL-C=264±58 mg/dL) who underwent 64-detector row 
CCTA without known coronary artery disease were retrospectively evaluated by assigning a score 
(0-5) to each of 17 coronary artery segments according to the Society of Cardiovascular Computed 
Tomography guidelines. Those scores were summed and subsequently natural log-transformed. The 
periods to major adverse cardiac events (MACE) were estimated using multivariable Cox 
proportional hazards models. During the follow-up period (median 941 days), 21 MACE had 
occurred. Receiver-operating characteristic curve analyses identified a plaque burden score of 3.35 
(raw score 28.5) as the optimal cutoff for predicting a worse prognosis. Multivariate Cox regression 
analysis identified the presence of a plaque score ≥ 3.35 as a significant independent predictor of 
MACE (HR=3.65; 95% CI 1.32 to 25.84, p<0.05). The regression equations were Y=0. 68X-15.6 
(r=0.54, p<0.05) in male and Y=0. 74X-24.8 (r=0. 69, p<0. 05) in female heterozygous FH patients. 
In conclusion, coronary plaque burden identified in a noninvasive, quantitative manner was 
significantly associated with future coronary events in Japanese patients with heterozygous FH and 
that coronary atherosclerosis may start to develop, on average, at 23 and 34 years of age in male and 
female heterozygous FH patients, respectively.  
 





Familial hypercholesterolemia (FH; OMIM #143890) is characterized by the triad of (1) 
primary hyper-LDL-cholesterolemia, (2) tendon xanthomas and (3) premature coronary artery 
disease (CAD).1,2 Coronary computed tomography angiography (CCTA), a noninvasive imaging 
modality that progressed during the last decade, permits accurate detection and exclusion of 
CAD.3-5 In addition, the prognostic utility of CCTA for the general population has been clearly 
demonstrated by a number of prior studies.6,7 However, few data exits regarding the clinical 
prognostic performance of CCTA in FH. Moreover, such modality could help us to estimate when 
and how rapidly coronary atherosclerosis in FH patients develop.8 Here, we build on these 
observations to test 2 hypotheses: (1) plaque burden assessed by CCTA are associated with 
future coronary events beyond established risk factors in FH patients; and (2) we can 
estimate the onset and progression of coronary atherosclerosis in FH patients assuming 
linear model of plaque progression. We tested these hypotheses in our mutation determined 
heterozygous FH cohort without known CAD. 
 
Methods 
A total of 104 consecutive FH patients without known CAD exhibiting a single mutation in the 
LDL receptor or proprotein convertase subtilisin/kexin type 9 (PCSK9) gene who underwent 
64-detector row CCTA between January 2008 and December 2012 due to any clinical indications, 
including chest symptom, signs of cardiac diseases, peripheral artery disease, cerebrovascular 
disease, or multiple coronary risk factors were retrospectively analyzed. Among a total of 104 
heterozygous FH patients, 3 subjects with poor images (2.9%) were excluded, thus, 101 subject 
whose ages range from 22 to 84 years with heterozygous FH patients remained in this analysis 
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(male = 52, mean age = 56±16 years, mean LDL-C = 264±58 mg/dL). The characteristics of the 
study subjects are listed in Table 1 and Supplementary Table 1. Median follow-up period was 941 
days. We defined major adverse cardiac events (MACE) as either cardiac death, ST elevated 
myocardial infarction (STEMI), non-ST elevated myocardial infarction (NSTEMI), unstable angina 
pectoris (UAP), staged percutaneous coronary intervention (PCI) or coronary artery bypass grafting 
(CABG). 
Hypertension was defined as systolic blood pressure of at least 140 mmHg, diastolic blood 
pressure of at least 90 mmHg, or use of antihypertensive medication. Presence of diabetes was 
defined as previously described by Japan Diabetes Society,9 or the use of diabetes medication. Body 
mass index (BMI) was defined as body weight in kilograms divided by the square of height 
measured in meters. Serum concentrations of total cholesterol, triglyceride, and HDL-C were 
determined enzymatically. LDL-C concentrations were calculated using the Friedewald formula.10 
Genomic DNA was isolated from peripheral blood white blood cells according to standard 
procedures and was used for PCR. Genotypes of all the participants in this study were determined 
as previously described.11-13 The institutional review board approved the study protocol. All patients 
gave written informed consent.  
 CCTA was performed with a dual source 64-slice (Somatom Definition Flash; Siemens Medical 
System, Erlangen, Germany). A noncontrast-enhanced scan was performed to assess coronary 
calcium and defined the anatomical range for subsequent CCTA. This scan was automatically 
triggered and performed using the following scan parameters: collimation, 0.6 mm; gantry rotation 
time, 280 ms; tube voltage, 120 kV; and tube current, 100 mA. For the contrast-enhanced scan, 
collimation was 0.6 mm and gantry rotation time was 280 ms. The tube voltage and current were 
120 kV and 340 mA, respectively. Fifty to 80 mL of nonionic iodinated contrast (370 mg iodine/mL, 
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Iopamidol-370, Bayer Healthcare Pharmaceuticals, Osaka, Japan) was injected using a dual-flow 
injector (Dual Shot GX, Nemoto Kyorindo, Tokyo, Japan) via an antecubital vein. The iodine load 
was based on body weight. Image acquisition was manually triggered upon arrival of contrast in the 
left main coronary trunk. Patients with a heart rate greater than 100 beats per minute and with no 
contraindications to beta-blockers received intravenous beta-blocker therapy (Landiolol 
Hydrochloride 0.125 mg/kg) just before the computed tomographic scan. Multiple phases were 
employed to assess the images of different arteries. In addition, we constructed three-dimensional 
rotation images to assess the diagonal and other small branches.  
 Two experienced radiologists, blinded with regard to the clinical status, evaluated all CCTA scans 
separately. In spite of our efforts, the segments that were uninterpretable were scored as the same as 
most proximal segment which was interpretable (72 segments among total of 1717 segments: 4.2%). 
Discrepancies in evaluation were resolved during a consensus reading. Angiographic analysis by 
coronary computed tomography was performed according to a 17-segment American Heart 
Association classification.14 Coronary plaque burden was assessed by assigning a score (0 to 5) to 
each of 17 coronary artery segments according to the Society of Cardiovascular Computed 
Tomography (SCCT) guidelines (0 Normal: absence of plaque and no luminal stenosis; 1 Minimal: 
plaque with < 25% stenosis; 2 Mild: 25%–49% stenosis; 3 Moderate: 50%–69% stenosis; 4 Severe: 
70%–99% stenosis; 5 Occluded).15 Those scores were summed and natural log-transformed, due to 
its skewed distribution.  
 Categorical variables were expressed as percentages. The Fisher exact test or chi-square test was 
used as appropriate. Continuous variables with a normal distribution were shown as mean (±SD), 
and were compared using unpaired Student’s t-tests. The plaque burden score cut-off value was 
determined on the basis of receiver-operating characteristic (ROC) curve analysis. The cumulative 
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fraction of events was estimated as 1 minus the Kaplan-Meier estimate of survival free of MACE. 
Differences in the cumulative fraction of events between subgroups were assessed by the log-rank 
test according to the cut-off. We initially analyzed all available risk factors using a univariate model, 
then multivariate Cox regression analysis was performed using only the covariates that were 
significantly associated with MACE in the univariate analysis. Intraobserver/interobserver 
variability between readers was assessed using the Bland-Altmann method, and coefficient of 
variation (CV) with 20 randomly selected subjects. All statistical analyses were conducted using 
R.16 All p values < 0.05 were considered statistically significant. 
 
Results 
The clinical characteristics of patients with or without subsequent MACE are shown in Table 1. 
The frequencies of the traditional coronary risk factors, such as age, hypertension, diabetes mellitus, 
smoking habits, and BMI were significantly higher while HDL-C was significantly lower in FH 
patients with MACE compared to those without MACE. Interestingly, plaque burden was 
significantly greater in FH patients with MACE than those without MACE. The genetic 
backgrounds of the study participants are shown in Supplementary Table 1. A nonsense mutation 
(c.2431A>T) in the LDL receptor gene was common (40%), and the remaining participants carried 
26 other different gene mutations, including PCSK9. 
Intra- and interobserver reproducibility for measurements of plaque burden scores are shown in 
Figure 1. Bland-Altman analysis demonstrated good agreements between both within intraobserver 
with a CV of 9.1% (Figure 1A) and within interobserver with a CV of 9.9% (Figure 1B) 
measurements.  
To evaluate if coronary plaque burden and traditional risk factors were determinants of the 
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occurrence of MACE, univariate analysis was performed (Table 2). The median of the coronary 
plaque burden score was 2.78 (raw score 16.1). As a result, age, hypertension, diabetes mellitus, 
smoking, BMI, and plaque burden score ≥ median were significant predictors for MACE (Table 2). 
In addition, multivariate analysis showed that the presence of hypertension and a plaque burden 
score ≥ median were significant independent prognostic factors (Table 2). 
Based on the ROC curve analysis, the optimal plaque burden score cutoff value for developing 
MACE was 3.35 (raw score 28.5), the sensitivity and specificity of which were 85.7% and 82.5%, 
respectively with an AUC of 0.90 (Figure 2A). Table 3 compares the clinical profiles of patients 
with a plaque burden score ≥ 3.35 and those with < 3.35. The frequencies of the traditional coronary 
risk factors, such as age, hypertension, diabetes mellitus, and smoking habit were higher in patients 
with a plaque burden score ≥ 3.35 than those < 3.35. Moreover, BMI and the duration under statin 
therapy were greater in patients with a plaque burden score ≥ 3.35 than those with a score < 3.35. 
The cumulative event rate curve revealed that those patients with a plaque burden score ≥ 3.35 
had a significantly higher event rate than those with a score < 3.35 (Figure 2B). Table 4 shows the 
MACE during the follow-up period. As many as 18 among 30 patients with a plaque burden score ≥ 
3.35 had MACE during the follow-up period. 
There was no one who exhibited coronary ostial stenosis associated with supravalvular stenosis 
which is specific to FH. However, as much as 26 among 101 (26%) heterozygous FH patients 
exhibited aortic valve calcification detected by CCTA.  
We also investigated if the particular mutation status (c.2431A>T) could affect any risk 
factors including lipids, as well as the outcomes; however, there is no difference observed 
in the group with this mutation and that with other mutations (Supplementary Table 2, 3). 
Finally, we evaluated the correlation coefficient between age and raw plaque burden score in 
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each gender (Figure 3). The regression equations were Y=0. 68X – 15.6 (r = 0.54, p < 0.05) in male 
and Y= 0. 74X – 24.8 (r = 0. 69, p < 0. 05) in female heterozygous FH patients even after 
accounting for other risk factors, such as LDL-C, HDL-C, hypertension, diabetes, smoking. These 
results suggest that coronary atherosclerosis may start to develop, on average, at 23 and 34 years of 
age in male and female heterozygous FH patients, respectively. 
 
Discussion 
In this study, we evaluated plaque burden score assessed with CCTA among mutation 
determined heterozygous FH patients and found that such score was associated with future 
coronary events beyond established risk factors, and that we can estimate the onset and 
progression of coronary atherosclerosis in FH patients assuming a linear model of plaque 
progression. 
Heterozygous FH have a mutant allele of either of three FH-associated genes (FH genes), 
namely LDL receptor, apolipoprotein B-100 or PCSK9 genes,17 and the frequency of which is 
estimated to be at least 1 in 500 general populations worldwide.18 Those patients exhibit premature 
coronary atherosclerosis due to extremely high LDL-C levels, thus their risk of future coronary 
events needs to be assessed. In the current study, plaque burden score assessed with CCTA 
successfully estimated future MACE. In addition to those prognostic values of plaque burden score, 
calculating those scores quantitatively based on SCCT guideline instead of adopting any other 
published dichotomized scoring system,5,19,20 we could estimate the onset and progression of CAD 
in FH patients assuming linear model of plaque progression. The regression lines from age and 
plaque score suggested that coronary atherosclerosis might start to develop at 23 and 34 years of 
age in male and female FH patients, respectively, even under statin therapy. In contrast, our 
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previous study, conducted before the approval of statins in 1989 showed that coronary artery 
stenosis detectable by conventional angiography occurred around 17 and 25 years of age in male 
and female FH patients, respectively.8 These differences in age (6 years in male, and 9 years in 
female) might reflect a delay in the development of coronary atherosclerosis using statin in patients 
with FH. We may consider the examination by CCTA around such ages in FH patients. 
There are only a few papers from Brazil, Spain and The Netherlands investigating the clinical 
application of CCTA for FH.21-24 Although those papers demonstrated that CCTA could detect 
substantial coronary plaque burden in FH, especially in mutation-positive FH, few of them 
addressed the simple issue regarding the predictive prognostic value of this modality. 
This study has several limitations. (1) This study was a retrospective analysis of data from a 
single center with a relatively small sample size, thus our results need to be validated through 
prospective multi-center studies. (2) Because some patients with FH were not examined by CCTA 
due to physicians’ and patients’ selection, there is likely to be some bias. (3) Although we have 
validated the reproducibility of this measurement, the assessments of stenotic severity of calcified 
plaque by CCTA were still difficult, leaving the possibility that plaque burden was overestimated. 
(4) Measurement of the Agatston score, which is widely used to assess the burden of coronary 
artery calcium in a quantitative manner,25 was not routinely available in this cohort. (5) Our 
assumption of the development of coronary atherosclerosis in FH is based on linear model (and on 
the findings from the age 22 to 84 years), which may not be applicable to the younger FH patients. 
(6) Majority of events occurred close after the CT scan, which reflected the fact that the findings of 
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Figure 1. Bland-Altman analysis for the measurement of plaque burden score 
Bland-Altman analysis demonstrated good agreements between the measurements (A) within 
intraobserver and (B) within interobserver. 
 
Figure 2. Receiver-operating characteristic (ROC) curve analysis and Survival analysis 
(A) Receiver-operating characteristic (ROC) curve analysis revealed a plaque burden score of 3.35 
as the optimal cutoff for predicting MACE, the sensitivity and specificity of which were 85.7% and 
82.5%, respectively with an AUC of 0.90. 
(B) Cumulative event rates according to the cut-off. Blue dotted line indicates subjects with a 
plaque burden score ≥ 3.35. Red solid line indicates subjects with a plaque burden score < 3.35. 
 
Figure 3. Plots of correlation between age (X) and plaque burden score (Y) in male (A) and female 
(B) heterozygous FH patients.  
The regression equations are Y=0.68X – 15.6 (r = 0.54, p < 0.05) in male heterozygotes, and Y= 
0.74X – 24.8 (r = 0. 69, p < 0. 05) in female heterozygotes, respectively. The solid lines indicate the 
regression line. The dotted lines indicate 95% confidence interval. Plaque burden score was 
obtained by assigning scores (0 to 5) to each of 17 coronary artery segments; the highest possible 
plaque burden score is 60. 
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Table 1. Baseline characteristics divided by the presence of major adverse cardiac event 
  Major adverse cardiac event    
Variable YES (n=21) NO (n=80) p value 
Age (years) 59.4±14.8 50.1±13.7 < 0.05 
Men 12 (57%) 40 (50%) n.s. 
Hypertension 19 (79%) 15 (19%) < 0.05 
Diabetes mellitus 11 (52%) 11 (14%) < 0.05 
Smoker 17 (81%) 19 (24%) < 0.05 
BMI (kg/m2) 25.8±3.8 23.4±2.9 < 0.05 
Total cholesterol (mg/dL) 339±54 347±62 n.s. 
Low-density lipoprotein cholesterol (mg/dL) 265±65 260±55 n.s. 
High-density lipoprotein cholesterol (mg/dL) 43±10 57±14 < 0.05 
Triglyceride (mg/dL) 147±60 132±80 n.s. 
Plaque burden score 3.64±0.33 2.13±1.25 < 0.05 
Statins 15 (71%) 52 (65%) n.s. 










Table 2. Univariate and multivariate Cox regression analysis of risk factors for major adverse cardiac event 
  Univariate analysis   Multivariate analysis 
Variable Hazard ratio 95% CI p value   Hazard ratio 95% CI p value 
Age 1.038 1.006-1.072 < 0.05 
    
Men 0.986 0.413-2.354 n.s. 
    
Hypertension 20.82 4.842-89.55 < 0.05 
 
7.521 1.581-37.76 < 0.05 
Diabetes mellitus 3.833 1.620-9.066 < 0.05 
    
Smoker 6.336 2.214-18.9 < 0.05 
    
Body mass index 1.171 1.037-1.324 < 0.05 
    
Total cholesterol 1.004 0.9972-1.011 n.s. 
    
Low-density lipoprotein cholesterol 1.005 0.9978-1.012 n.s. 
    
High-density lipoprotein cholesterol 0.9773 0.9449-1.011 n.s. 
    
Triglyceride 1.002 0.9966-1.007 n.s. 
    
plaque burden score ≥ median (2.78) 13.93 4.082-47.51 < 0.05 
 
5.424 1.411-20.85 < 0.05 











Table 3. Baseline characteristics divided by the plaque score cut-off value 
Variable 
Plaque burden score 
p value 
≥ 3.35 (n=32) < 3.35 (n=69) 
Age (years) 61.0±13.7 48.0±12.8 < 0.05 
Men 15 (47%) 37 (54%) n.s. 
Hypertension 23 (72%) 11 (16%) < 0.05 
Diabetes mellitus 15 (47%) 7 (10%) < 0.05 
Smoker 19 (59%) 17 (25%) < 0.05 
Body mass index (kg/m2) 25.7±3.3 23.1±2.9 < 0.05 
Total cholesterol (mg/dL) 341±49 346±59 n.s. 
Low-density lipoprotein cholesterol (mg/dL) 262±70 264±53 n.s. 
High-density lipoprotein cholesterol (mg/dL) 44±12 56±13 < 0.05 
Triglyceride (mg/dL) 129±84 138±99 n.s. 
Plaque burden score 3.68±0.22 1.86±1.15 < 0.05 
Statins 25 (78%) 42 (61%) n.s. 








Table 4. Major adverse cardiac event during the follow-up period 
Variable 
Plaque burden score 
p value 
≥ 3.35 (n=32) < 3.35 (n=69) 
Composite endpoint 
    All major adverse cardiac event 18 (56%) 3 (4%) < 0.05 
 Acute coronary syndrome-related event 5 (16%) 0 (0%) n.s. 
Coronary events 
    Cardiac death 1 (3%) 0 (0%) n.s. 
 ST elevated myocardial infarction 2 (6%) 0 (0%) n.s. 
 Unstable angina pectoris/non-ST elevated myocardial infarction 2 (6%) 0 (0%) n.s. 
 Staged-PCI/CABG 13 (41%) 3 (4%) < 0.05 






















































AUC = 0.90 
Plaque score < 3.35 
Plaque score ≥ 3.35 
Receiver-operating characteristic curve Cumulative incidents 
Figure 2 
Male Female 





























Supplementary Table1. Genetic backgrounds
Gene
Nucleotide





LDLR c.68-?_313+?del Large deletion Truncated protein 5
LDLR c.191-?_940+?dup Large duplication Truncated protein 2
LDLR c.344G>A Missense Arg-His 1
LDLR c.413C>G Nonsense Ser-stop 3
LDLR c.539G>A Nonsense Trp-stop 1
LDLR c.662_665dupACTG Duplication Frameshift/stop 1
LDLR c.682G>A Missense Glu-Lys 2
LDLR c.797A>G Missense Asp-Gly 1
LDLR c.901G>T Missense Asp-Tyr 1
LDLR c.1012T>A Missense Cys-Ser 2
LDLR c.1285G>A Missense Val-Met 1
LDLR c.1297G>C Missense Asp-His 2
LDLR c.137G>A Missense Cys-Tyr 1
LDLR c.1432G>A Missense Gly-Ala 1
LDLR c.1474G>A Missense Asp-Asn 1
LDLR c.1567G>A Missense Val-Met 1
LDLR c.1689dupC Duplication Frameshift/stop 1
LDLR c.1702C>G Missense Leu-Val 1
LDLR c.1778dupG Duplication Frameshift/stop 1
LDLR c.1845+2T>C Splicing exon13 skip 1
LDLR c.1871_1873delTCA Deletion 603 Ile deletion 3
LDLR c.2054C>T Missense Pro-Leu 6
LDLR c.2140+1G>T Splicing exon15 skip 2
LDLR c.2141-?_2311+?del Large deletion Truncated protein 3
LDLR c.2312-3C>A Splicing exon16 skip 9
LDLR c.2431A>T Nonsense Lys-stop 41
PCSK9 c.94G>A Missense Glu-Lys 7
LDLR: LDL receptor
Supplemental Table 2. Baseline characteristics d    
c.2431A>T (n=41) Others (n=60)
Age (years) 55.9±14.4 56.2±13.9
Men 23 (56%) 29 (48%)
Hypertension 16 (39%) 18 (30%)
Diabetes mellitus 11 (27%) 11 (18%)
Smoker 17 (41%) 19 (32%)
Body mass index (kg/m2) 23.8±3.5 24.1±4.0
Total cholesterol (mg/dL) 344±47 346±56
Low-density lipoprotein cholesterol (mg/dL) 264±66 265±49
High-density lipoprotein cholesterol (mg/dL 52±11 55±10
Triglyceride (mg/dL) 142±76 139±104
Plaque burden score 2.38±0.20 2.46±0.34
Statins 30 (73%) 37 (62%)
Statins duration (years) 7.5±8.4 7.7±8.6
Variable
Genotype

















　All major adverse cardiac event 10 (24%)
　Acute coronary syndrome-related event 2 (5%)
Coronary events
　Cardiac death 1 (2%)
　ST elevated myocardial infarction 1 (2%)




PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting
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